[Antagonistic effect of 12-lipoxygenase inhibitor ML355 on lipopolysaccharide induced inflammatory response in mice]

Xingyu Wang1, Wanqi Tang2, Tao Chen1

  • 1Department of Intensive Care Unit, the Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China.

Abstract

Insights

ML355, a 12-lipoxygenase inhibitor, effectively reduces lipopolysaccharide (LPS)-induced inflammation in mice by suppressing key inflammatory markers and pathways. This study highlights ML355

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Lipopolysaccharide (LPS) triggers significant inflammatory responses.
  • 12-lipoxygenase (12-LOX) plays a role in inflammatory processes.
  • ML355 is a known inhibitor of 12-LOX.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of ML355 on LPS-induced inflammation in mice.
  • To elucidate the molecular mechanisms underlying ML355's action.

Main Methods:

  • In vivo studies using C57BL/6 mice treated with LPS and varying doses of ML355.
  • In vitro experiments using mouse peritoneal macrophages (PMs) stimulated with LPS and ML355.
  • Analysis of inflammatory mediators (12-HETE, IFN-γ, IL-1β, IL-6, TNF-α) via ELISA.
  • Gene expression analysis (qRT-PCR) and protein expression analysis (Western blotting) of inflammatory markers and signaling pathways (MAPK).

Main Results:

  • ML355 significantly reduced levels of 12-HETE and inflammatory cytokines (IFN-γ, IL-1β) in vivo and in vitro.
  • ML355 pretreatment decreased mRNA expression of IFN-γ and IL-1β in PMs.
  • ML355 inhibited the expression of 12/15-LOX and phosphorylation of ERK and JNK proteins in the MAPK pathway.

Conclusions:

  • ML355 exhibits an antagonistic effect on LPS-induced inflammatory responses in mice.
  • The anti-inflammatory action of ML355 is associated with the suppression of 12/15-LOX, p-ERK, and p-JNK.